As part of the extended field trial for DeepVerge’s Microtox PD unit, its COVID-19 enabled near-source wastewater contamination test system, deployment into a number ofIrish water treatment plants has now commenced.
Similar arrangements across multiple sites in Northern England are also expected shortly with first shipments to China and the US following by the year-end. The data acquired through this exercise, combined with modelling through the Group’s Rinocloud artificial intelligence division, is expected to offer potential to predict the growth trajectory of future coronavirus (or other dangerous pathogens) clusters, thereby providing an urgently needed, localised early warning system.
Clearly, access to such unique technologies remains a key element for global populations seeking to return to some sort of post-Pandemic ‘normality’. With the expectation that the Group will be able to successfully commercialise Microtox PD before H2 2021 followed by multinational roll-out through its established international customer network, DeepVerge’s ability to adequately service the overwhelming international demand it prospectively faces may become the most significant challenge going forward as it seeks to satisfy what has potential to become an exceptionally rewarding, high-margin global opportunity.
We would draw your attention to the various disclaimers in the document both at the beginning and at the end of the note. Retail clients (as defined by the rules of the FCA) must not rely on the research document. In particular you should note that the research document is a non-independent marketing communication. The analyst who has prepared the research is aware that TPI provides research to DeepVerge plc. Accordingly the research has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibitions on dealing ahead of its dissemination.
The information in the document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.
Copyright © 2019 Turner Pope Investments (TPI) Limited, all rights reserved.
